Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by HEPACAM is a single-pass type I membrane protein that localizes to the cytoplasmic side of the cell membrane. Additionally we are shipping Hepatic and Glial Cell Adhesion Molecule Proteins (11) and Hepatic and Glial Cell Adhesion Molecule Kits (4) and many more products for this protein.
Showing 10 out of 48 products:
Human Polyclonal HEPACAM Primary Antibody for EIA, WB - ABIN952712
Yang, Wu, Luo, Pan, Pu: Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma. in World journal of urology 2010
Show all 3 references for ABIN952712
Human Polyclonal HEPACAM Primary Antibody for WB - ABIN656770
Davila, Froeling, Tan, Bonnard, Boland, Snippe, Hibberd, Seielstad: New genetic associations detected in a host response study to hepatitis B vaccine. in Genes and immunity 2010
Show all 2 references for ABIN656770
Human Polyclonal HEPACAM Primary Antibody for IF (p), IHC (p) - ABIN758651
Maes, McGill, da Silva, Abels, Lebofsky, Maria Monteiro de Araújo, Tiburcio, Veloso Alves Pereira, Willebrords, Crespo Yanguas, Farhood, Beschin, Van Ginderachter, Zaidan Dagli, Jaeschke, Cogliati et al.: Involvement of connexin43 in acetaminophen-induced liver injury. ... in Biochimica et biophysica acta 2016
Due to the ability to reactivate expression of hepaCAM and inhibit growth of bladder cancer cells, AZAC may represent an effective treatment for bladder cancer.
The extracellular domain of GlialCAM is necessary for cell junction targeting and for mediating interactions with itself or with MLC1 and ClC-2 (show CLCN2 Antibodies).
HepaCAM may prevent the translocation of PKCepsilon (show PRKCE Antibodies) from cytosolic to particulate fractions, resulting in the inhibition of 786-0 cell proliferation.
GlialCAM is able to interact with all CLC (show CLC Antibodies) channels tested in this study, targeting them to cell junctions and activating them by stabilizing the open configuration of the common gate
Results allow classifying the effect of HEPACAM gene mutations in different subtypes and authors indicate different cellular mechanisms that lead to megalencephalic leukoencephalopathy pathogenesis.
we demonstrate an evolutionary conserved role for MLC1 in regulating glial surface levels of GLIALCAM, and this interrelationship explains why patients with mutations in either gene (MLC1 or GLIALCAM) share the same clinical phenotype.
High expression of hepaCAM is associated with renal carcinoma (show TSC2 Antibodies).
analysis of mutations in GLIALCAM in patients with megalencephalic leukoencephalopathy with subcortical cysts [case report]
results suggested that HepaCAM acted as a tumor suppressor in prostate cancer
Re-activation of hepaCAM gene by 5-aza-CdR (show RUNX1T1 Antibodies) can inhibit growth of cancer cells and arrest cells at G0/G1 phase
Data indicate that membrane protein MLC1 is crucial for proper localization of adhesion molecule (show NCAM1 Antibodies) GlialCAM and chloride channel (show CLCA1 Antibodies) ClC-2 (show CLCN2 Antibodies), and for changing ClC-2 (show CLCN2 Antibodies) currents.
GlialCAM, an immunoglobulin-like cell adhesion molecule (show MCAM Antibodies) is expressed in glial cells of the central nervous system.
The protein encoded by this gene is a single-pass type I membrane protein that localizes to the cytoplasmic side of the cell membrane. The encoded protein acts as a homodimer and is involved in cell motility and cell-matrix interactions. The expression of this gene is downregulated or undetectable in many cancer cell lines, so this may be a tumor suppressor gene.
hepatocyte cell adhesion molecule
, protein hepaCAM